Citations (70)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Peter Novodvorský & Martin Haluzík. (2022) An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus. Expert Opinion on Drug Safety 21:3, pages 349-361.
Read now
Read now
Abraham Edgar Gracia-Ramos, Juana Carretero-Gómez, Carlos E. Mendez & Francisco Javier Carrasco-Sánchez. (2022) Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients. Current Medical Research and Opinion 38:1, pages 43-53.
Read now
Read now
Josh Reed, Stephen Bain & Venkateswarlu Kanamarlapudi. (2021) A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes, Metabolic Syndrome and Obesity 14, pages 3567-3602.
Read now
Read now
Stephen A. Brunton. (2020) Introducing a novel therapy for type 2 diabetes to primary care. Postgraduate Medicine 132:sup2, pages 1-2.
Read now
Read now
Stephen A. Brunton & Carol H. Wysham. (2020) GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgraduate Medicine 132:sup2, pages 3-14.
Read now
Read now
Vivian T Thieu, Susan Robinson, Tessa Kennedy-Martin, Kristina S Boye & Luis-Emilio Garcia-Perez. (2019) Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes. Patient Preference and Adherence 13, pages 561-576.
Read now
Read now
Manel Mata-Cases, Josep Franch-Nadal, Emilio Ortega, Jordi Real, Mònica Gratacòs, Bogdan Vlacho & Dídac Mauricio. (2019) Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area. Current Medical Research and Opinion 35:10, pages 1735-1744.
Read now
Read now
Articles from other publishers (63)
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner & Erhard Siegel. (2023) Therapie des Typ-2-DiabetesTreatment of type 2 diabetes. Die Diabetologie 19:5, pages 658-697.
Crossref
Crossref
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana Isaacs, Eric L. Johnson, Scott Kahan, Kamlesh Khunti, Jose Leon, Sarah K. Lyons, Mary Lou Perry, Priya Prahalad, Richard E. Pratley, Jane Jeffrie Seley, Robert C. Stanton & Robert A. Gabbay. (2023)
9. Pharmacologic Approaches to Glycemic Treatment:
Standards of Care in Diabetes—2023
. Diabetes Care 46:Supplement_1, pages S140-S157.
Crossref
Crossref
Hideaki Kaneto, Mike Baxter, Yoko Takahashi & Yasuo Terauchi. (2022) Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL). Advances in Therapy 39:12, pages 5453-5473.
Crossref
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner & Erhard Siegel. (2022) Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology & Diabetes 130:S 01, pages S80-S112.
Crossref
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner & Erhard Siegel. (2022) Therapie des Typ-2-DiabetesTreatment of type 2 diabetes. Die Diabetologie 18:5, pages 623-656.
Crossref
Crossref
Yasuo Terauchi, Makiko Usami & Tomoyuki Inoue. (2022) The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study. Advances in Therapy 39:6, pages 2873-2888.
Crossref
Crossref
Rui Song, Hang Qian, Yunlian Wang, Qingmei Li, Dongfeng Li, Jishun Chen, Jingning Yang, Jixin Zhong, Handong Yang, Xinwen Min, Hao Xu, Yong Yang & Jun Chen. (2022) Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists. Journal of Diabetes Research 2022, pages 1-8.
Crossref
Crossref
Jason T. Alexander, Erin M. Staab, Wen Wan, Melissa Franco, Alexandra Knitter, M. Reza Skandari, Shari Bolen, Nisa M. Maruthur, Elbert S. Huang, Louis H. Philipson, Aaron N. Winn, Celeste C. Thomas, Meltem Zeytinoglu, Valerie G. Press, Elizabeth L. Tung, Kathryn Gunter, Brittany Bindon, Sanjay Jumani & Neda Laiteerapong. (2021) The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. Journal of General Internal Medicine 37:2, pages 415-438.
Crossref
Crossref
Valeh Mirzazada, Sadagat Sultanova, Natavan Ismayilova, Aygun Huseynova, Gulnara Nurmammadova, Sevil Ismayilova & Aygun Aliyeva. 2022. Cardiovascular Diseases [Working Title]. Cardiovascular Diseases [Working Title].
. (2022)
9. Pharmacologic Approaches to Glycemic Treatment:
Standards of Medical Care in Diabetes—2022
. Diabetes Care 45:Supplement_1, pages S125-S143.
Crossref
Crossref
Lola A. Coke, Prakash C. Deedwania, Debbie Hinnen, Melissa Magwire & Nancy H. Miller. (2022) GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice. Journal of the American Association of Nurse Practitioners 34:2, pages 418-440.
Crossref
Crossref
Jiwoo Lee, Hwi Seung Kim, Chang Hee Jung, Joong‐Yeol Park & Woo Je Lee. (2021) Switching from insulin to dulaglutide therapy in patients with type 2 diabetes: A real‐world data study. Diabetes/Metabolism Research and Reviews 37:8.
Crossref
Crossref
Julio Rosenstock, Rifat Emral, Leobardo Sauque-Reyna, Viswanathan Mohan, Carlos Trescolí, Saud Al Sifri, Nebojsa Lalic, Agustina Alvarez, Pascaline Picard, Mireille Bonnemaire, Nacima Demil & Rory J. McCrimmon. (2021) Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. Diabetes Care 44:10, pages 2361-2370.
Crossref
Crossref
Jun Xu, DanZhen Yao & JinYing Xia. (2021) Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta‐analysis. Journal of Clinical Pharmacy and Therapeutics 46:5, pages 1245-1253.
Crossref
Crossref
Pei Shang, Matthew Baker, Samantha Banks, Sa-Ik Hong & Doo-Sup Choi. (2021) Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists. Journal of Movement Disorders 14:3, pages 193-203.
Crossref
Crossref
Charlotte Granhall, Tine A. Bækdal, Astrid Breitschaft, Flemming L. Søndergaard, Thomas W. Anderson & Mette Thomsen. (2021) Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration. Diabetes Therapy 12:9, pages 2599-2610.
Crossref
Crossref
Hae Jin Kim. (2021) Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist. The Journal of Korean Diabetes 22:2, pages 126-133.
Crossref
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Hans-Martin Reuter & Erhard Siegel. (2021) Therapie des Typ-2-DiabetesTherapy of type 2 diabetes. Der Diabetologe 17:4, pages 422-447.
Crossref
Crossref
Kirsi Norrbacka, Antoni Sicras-Mainar, Jeremie Lebrec, Esther Artime, Silvia Díaz, Santiago Tofé-Povedano, Ignacio Hernández & Irene Romera. (2021) Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain. Diabetes Therapy 12:5, pages 1535-1551.
Crossref
Crossref
Benedetta Maria Bonora, Mauro Rigato, Vera Frison, Michele D'Ambrosio, Federica Tadiotto, Annunziata Lapolla, Natalino Simioni, Agostino Paccagnella, Angelo Avogaro & Gian Paolo Fadini. (2021) Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care. Diabetes Research and Clinical Practice 173, pages 108686.
Crossref
Crossref
Stefanos Torkos, Jacqueline M. Burke & Kathy Zaiken. (2020) Evaluation of Patient Factors Associated With Achieving Goal Hemoglobin A1c in Collaborative Drug Therapy Management Ambulatory Care Clinics by Clinical Pharmacists: A Retrospective Chart Review. Journal of Pharmacy Technology 37:1, pages 3-11.
Crossref
Crossref
. (2021)
9. Pharmacologic Approaches to Glycemic Treatment:
Standards of Medical Care in Diabetes—2021
. Diabetes Care 44:Supplement_1, pages S111-S124.
Crossref
Crossref
Ja Young Jeon & Hae Jin Kim. 2021. Stroke Revisited: Diabetes in Stroke. Stroke Revisited: Diabetes in Stroke
167
177
.
Kacie Doyle-Delgado, James J. ChamberlainJay H. Shubrook, Neil Skolnik & Jennifer Trujillo. (2020) Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Annals of Internal Medicine 173:10, pages 813-821.
Crossref
Crossref
Nai-Pin Lin & Rong-Jie Chein. (2020) Total synthesis and absolute structure of N55, a positive modulator of GLP-1 signaling. Organic & Biomolecular Chemistry 18:43, pages 8899-8907.
Crossref
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Hans-Martin Reuter & Erhard Siegel. (2020) Therapie des Typ-2-Diabetes. Diabetologie und Stoffwechsel 15:S 01, pages S65-S92.
Crossref
Crossref
Jian Kuang, Jiankun Zhu, Siying Liu & Quanmin Li. (2020) Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies. Diabetes Therapy 11:10, pages 2329-2339.
Crossref
Crossref
Li Wang, Xiangyang Liu, Wenjuan Yang, Jingbo Lai, Xinwen Yu, Jianrong Liu, Xiling Gao, Jie Ming, Kaiyan Ma, Jing Xu, Zhufang Tian, Qingzhen He & Qiuhe Ji. (2020) Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial. Diabetes Therapy 11:10, pages 2313-2328.
Crossref
Crossref
Hideaki Kaneto, Ryusuke Koshida & Mike Baxter. (2020) Fixed‐ratio combination of basal insulin and glucagon‐like peptide‐1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge. Diabetes, Obesity and Metabolism 22:S4, pages 24-34.
Crossref
Crossref
Richard J. MacIsaac. (2020) Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?. Diabetes Therapy 11:8, pages 1627-1638.
Crossref
Crossref
Kevin Cowart. (2020) Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin. Clinical Diabetes 38:3, pages 304-310.
Crossref
Crossref
Susan Robinson, Kristina S. Boye, Reema Mody, Alena Antonie Strizek, Manige Konig, Raleigh E. Malik & Tessa Kennedy-Martin. (2020) Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review. Diabetes Therapy 11:7, pages 1437-1466.
Crossref
Crossref
Mike Baxter, Yukiko Morimoto, Masami Tamiwa, Masakatsu Hattori, Xuejun Victor Peng, Robert Lubwama & Hiroshi Maegawa. (2020) A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes. Diabetes Therapy 11:7, pages 1481-1496.
Crossref
Crossref
Melanie J. Davies, Cristina Bianchi & Stefano Del Prato. (2020) Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. Metabolism 107, pages 154242.
Crossref
Crossref
Kazuhiro Sugimoto, Yuji Tanaka, Takashi Sozu, Hiroshi Nishiyama, Takehiko Hoshino, Yuko Watanabe, Akira Tamura, Setsu Ohta, Toshiro Yamazaki, Susumu Suzuki & Takuro Shimbo. (2020) Association of One-Leg Standing Time with Discontinuation of Injectable Medications During Hospitalization Among Patients with Type 2 Diabetes. Diabetes Therapy 11:5, pages 1179-1190.
Crossref
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller-Wieland, Michael A. Nauck, Hans-Martin Reuter & Erhard Siegel. (2020) Therapie des Typ-2-DiabetesTherapy of type 2 diabetes. Der Diabetologe 16:3, pages 266-287.
Crossref
Crossref
L. Meneghini, A. Doshi, D. Gouet, T. Vilsbøll, K. Begtrup, P. Őrsy, M. F. Ranthe & I. Lingvay. (2019)
Insulin degludec/liraglutide (
ID
egLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
. Diabetic Medicine 37:2, pages 267-276.
Crossref
Crossref
. (2020)
9. Pharmacologic Approaches to Glycemic Treatment:
Standards of Medical Care in Diabetes—2020
. Diabetes Care 43:Supplement_1, pages S98-S110.
Crossref
Crossref
Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah & Sheldon W. Tobe. (2019) Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis. Endocrinology, Diabetes & Metabolism 3:1.
Crossref
Crossref
Fernando Moreno Obregón, José Pablo Miramontes-González, Catalina Romo Guajardo-Fajardo, Ángel Nieto-Sánchez, José Manuel López-Suárez, Javier Martín-Vallejo, Yolanda Arco-Prados, María Dolores García de Lucas & David León-Jiménez. (2019) Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months. Diabetes Research and Clinical Practice 158, pages 107916.
Crossref
Crossref
Omar G. Mustafa & Martin B. Whyte. (2019) The use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential. Diabetes/Metabolism Research and Reviews 35:8.
Crossref
Crossref
Kornelia Konz. (2019) Die neue individuelle antihyperglykämische Therapie bei Typ-2-Diabetes. Info Diabetologie 13:5, pages 30-37.
Crossref
Crossref
Josep Franch-Nadal, Manel Mata-Cases, Emilio Ortega, Jordi Real, Mònica Gratacòs, Bogdan Vlacho, Joan Antoni Vallés & Dídac Mauricio. (2019) Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia. Journal of Clinical Medicine 8:9, pages 1389.
Crossref
Crossref
Anastasia-Stefania Alexopoulos & John B. Buse. (2019) Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism 98, pages 104-111.
Crossref
Crossref
Hakan Dogruel & Mustafa Kemal Balci. (2019) Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future. World Journal of Diabetes 10:8, pages 446-453.
Crossref
Crossref
Fernando Álvarez-Guisasola, Domingo Orozco-Beltrán, Ana M. Cebrián-Cuenca, Manuel Antonio Ruiz Quintero, Escarlata Angullo Martínez, Luis Ávila Lachica, Carlos Ortega Millán, Elena Caride Miana, Jorge Navarro-Pérez, Julio Sagredo Perez, Joan Barrot de la Puente & Francesc Xavier Cos Claramunt. (2019) Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2. Atención Primaria 51:7, pages 442-451.
Crossref
Crossref
Roy Rasalam, John Barlow, Mark Kennedy, Pat Phillips & Alan Wright. (2019) GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective. Diabetes Therapy 10:4, pages 1205-1217.
Crossref
Crossref
Sebastian Niezen, Humberto Diaz del Castillo, Lumen A. Mendez Castaner & Alessia Fornoni. (2019) Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. Endocrinology, Diabetes & Metabolism 2:3.
Crossref
Crossref
Yunxia Tao, Gaoran Ge, Qing Wang, Wei Wang, Wenhao Zhang, Jiaxiang Bai, Jiayi Lin, Jining Shen, Xiaobin Guo, Yaozeng Xu & Dechun Geng. (2019) Exenatide Ameliorates Inflammatory Response in Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes. IUBMB Life.
Crossref
Crossref
Kibum KimSudhir UnniCarrie McAdam-MarxSheila M. ThomasKimberly L. SterlingCody J. OlsenBryan JohnstoneMatt MitchellDiana Brixner. (2019) Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents. Journal of Managed Care & Specialty Pharmacy 25:3, pages 314-322.
Crossref
Crossref
Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta & Jesús Reviriego. (2018) A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. Diabetes Therapy 10:1, pages 5-19.
Crossref
Crossref
. (2019)
9. Pharmacologic Approaches to Glycemic Treatment:
Standards of Medical Care in Diabetes—2019
. Diabetes Care 42:Supplement_1, pages S90-S102.
Crossref
Crossref
Salman Azhar, Stefanie Bittner, Jie Hu, Wen-Jun Shen, Yuan Cortez, Xiao Hao, Lu Han, Jens O. Lagerstedt, Fredric B. Kraemer & Jan O. Johansson. (2019) Novel ABCA1 peptide agonists with antidiabetic action. Molecular and Cellular Endocrinology 480, pages 1-11.
Crossref
Crossref
Melanie J. DaviesDavid A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J. Wexler & John B. Buse. (2018) Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41:12, pages 2669-2701.
Crossref
Crossref
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J. Wexler & John B. Buse. (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61:12, pages 2461-2498.
Crossref
Crossref
Lawrence Blonde & Vivian Fonseca. (2018) Glucagon-Like Peptide 1 Receptor Agonists For Type 2 Diabetes: A Comprehensive Review of How to Weigh The Options, Select the Right Patients, and Maximize Benefits. Endocrine Practice 24, pages 8-19.
Crossref
Crossref
Michael HeileKathleen WyneLiana K. BillingsAnthony CannonYehuda HandelsmanMichael Shannon. (2018) Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S42-S52.
Crossref
Crossref
Janet McGill. (2018) Introduction. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S3-S4.
Crossref
Crossref
Yehuda HandelsmanKathleen WyneAnthony CannonMichael ShannonDoron Schneider. (2018) Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S14-S29.
Crossref
Crossref
Yu. V. Natochin, A. V. Kutina, A. S. Marina & E. I. Shakhmatova. (2018) Stimulus for Glucagon-Like Peptide 1 Secretion in Rats. Doklady Biological Sciences 479:1, pages 57-59.
Crossref
Crossref
Susan Tran, Ravi Retnakaran, Bernard Zinman & Caroline K. Kramer. (2018) Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 20, pages 68-76.
Crossref
Crossref
Huiying Qiao, Haiyan Ren, He Du, Minfang Zhang, Xiaofang Xiong & Rong Lv. (2018) Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway. Molecular Medicine Reports.
Crossref
Crossref
Diego Bellido, Pablo Abellán, José Manuel Ruiz Palomar, Rogelio Álvarez Sintes, Andreu Nubiolae, Virginia Bellido & Gracia Romero. (2018) Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study. Current Therapeutic Research 89, pages 37-42.
Crossref
Crossref